Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00624338
Show Display Options
Rank Status Study
1 Completed
Has Results
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Atacicept 75 mg;   Drug: Atacicept 150 mg;   Other: Placebo Comparator

Study has passed its completion date and status has not been verified in more than two years.